Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia and Disorders with Psychotic Features
Karolinska Schizophrenia Project
KaSP is a multimodal observational study with the goal of clarifying underlying mechanisms that cause psychotic disorders, such as schizophrenia.
- Trial name
- KaSP (NCT06872463)
- Where
- Sweden
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Motivational Interviews, Schizophrenia
Motivational Interviewing in Patients With Schizophrenia
Introduction: A poor therapeutic relationship, low insight and lack of motivation are associated with poor adjustment (to symptoms, treatment, and environment) in patients with schizophrenia.
- Trial name
- NCT04941352
- Testing
- 6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Pamukkale University
Schizophrenia
A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients
An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
- Trial name
- NCT01086748
- Testing
- Risperidone, LY2140023
- Where
- 28 sites in United States, Croatia and 1 more
- Volunteers
- 1,134 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia, Therapeutics
Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia
The study was a 8-week, randomized, double-blind, placebo-controlled trial. Berberine (300 mg，three times a day), as an adjuvant therapy has been used on the basis of the Second-generation antipsychotics（SGAs） monotherapy.
- Trial name
- NCT03548155
- Testing
- Berberine, atypical antipsychotic
- Volunteers
- 65 people
- Sponsor
- Tianjin Anding Hospital
Schizophrenia, Schizoaffective Disorder
Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
Background: In this proposed study, we aim to investigate safety and efficacy of two synthetic retinoids - bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) and…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Cognition
- Trial name
- NCT00534898
- Testing
- Bexarotene, Fenretinide
- Where
- Israel
- Sponsor
- Beersheva Mental Health Center
Schizophrenia
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
This study evaluates PERSERIS at a higher dose than what has been administered in previous clinical trials. Subjects with stable schizophrenia on a dose of 5-6 mg oral risperidone will be switched to PERSERIS at the higher dose…
- Trial name
- NCT03978832
- Testing
- PERSERIS, Risperidone
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Indivior Inc.
Schizophrenia, Schizoaffective Disorder
Conversion to Antipsychotic Monotherapy
This is a 12-week, with a 32-week follow-up, rater-blind, randomized controlled trial to determine whether patients with chronic schizophrenia or schizoaffective disorder receiving two different antipsychotics simultaneously will…
- Trial name
- MOPE (NCT01368458)
- Testing
- Conversion to Antipsychotic Monotherapy
- Volunteers
- 24 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous…
- Trial name
- NCT00313391
- Testing
- Risperdal Consta
- Where
- United States
- Sponsor
- Emory University
Quality of Life, Well-Being
Psychoeducation in Patients Who Diagnosed With Schizophrenia
People with schizophrenia are faced with social problems such as repeated hospitalizations, stigma with lack of social skills, unemployment, lack of necessary and adequate health care and education due to lack of adequate care in…
- Conditions
- Quality of Life, Well-Being, Compliance, Treatment
- Trial name
- NCT04280835
- Testing
- Group Psychoeducation that Focused on Social Skill Development
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Gazi University
Schizophrenia, Auditory Hallucination
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication…
- Conditions
- Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
- Trial name
- NCT05299749
- Testing
- stg-rt-fMRI-Neurofeeback
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Boston VA Research Institute, Inc.
Schizophrenia Cognition Autobiographical Memory Cognitive Remediation, SCHIZOPHRENIA 1 (Disorder)
Acceptability and Efficacy of Group Reminiscence Intervention in a Sample of Patients With Schizophrenia
The study aimed to test whether group reminiscence intervention for inpatients with schizophrenia is feasible, acceptable and preliminary effective.
- Conditions
- Schizophrenia Cognition Autobiographical Memory Cognitive Remediation, SCHIZOPHRENIA 1 (Disorder), Hospitalized Adult Patients
- Trial name
- NCT07512843
- Testing
- Group reminiscence therapy
- Where
- Jordan
- Volunteers
- 38 people
- Sponsor
- The Hashemite University
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
- Trial name
- NCT03669640
- Testing
- RO6889450
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Effects of Pilates Exercise Program in Patients With Schizophrenia
Schizophrenia is one of the most frequent psychiatric disorders with a prevalence of 0.5-1.0 % all over the world. It remains one of the major reasons for disability although medical and psychosocial interventions.
- Trial name
- NCT03714698
- Testing
- Pilates exercise group, Control Group
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Hacettepe University
Schizophrenia
Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients
The purpose of the study is to compare the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme with to the current approved label titration.
- Trial name
- NCT00254787
- Testing
- IR (Immediate-Release) quetiapine fumarate (drug)
- Where
- 6 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Schizophrenia
Cognitive and Emotional Factors in Visual Exploration Among Patients With Schizophrenia
Background: Patients with schizophrenia are abnormally disturbed by information onsets, which may result in a disadvantage in filtering relevant information.
- Trial name
- SAILLANCE1 (NCT02874482)
- Where
- France
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Agitation
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this…
- Trial name
- NCT01400113
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Unity Health Toronto
Schizophrenia
Digital Voice Analysis in Patients With Schizophrenia
There is a differences in voice frequency of schizophrenic patients compared to patients with other mental diseases and compared to mentally healthy people.
- Trial name
- NCT00524979
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BeerYaakov Mental Health Center
Overweight and Obesity, Metabolic Cardiovascular Syndrome
The Effects of Psyllium Seed on Body Weight and Metabolic Syndrome Indicators in Patients with Schizophrenia
The research employs a quasi-experimental design, aiming to enroll 24 hospitalized patients with schizophrenia from 2hospitals in the central region, guided by G Power calculations.
- Conditions
- Overweight and Obesity, Metabolic Cardiovascular Syndrome, Schizophrenia, Disorganized
- Trial name
- NCT06789471
- Testing
- psyllium husk
- Where
- Taiwan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ru-Shin Zhang
Schizophrenia
Cognitive Behavioral Therapy Added to Risperidone for Schizophrenia
This study evaluated whether cognitive behavioral therapy (CBT), when added to risperidone treatment, improves cognitive function and serum brain-derived neurotrophic factor (BDNF) levels in patients with schizophrenia.
- Trial name
- CBT-BDNF-SCZ (NCT07609953)
- Testing
- Risperidone 4 to 6 mg/day, Cognitive Behavioral Therapy
- Where
- Indonesia
- Volunteers
- 42 people
- Sponsor
- Hasanuddin University
Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia
This study is an exploratory proof of mechanism (POM) study using PET/functional magnetic resonance imaging (fMRI) in a 2-period, 2-sequence, crossover design.
- Trial name
- NCT06880328
- Testing
- Ralmitaront, Radiolabeled PET tracer [18F]-DOPA
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.